Log in

ASX:GTGGenetic Technologies Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 8412 7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7,628.00
Book ValueA$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive GTG News and Ratings via Email

Sign-up to receive the latest news and ratings for GTG and its competitors with MarketBeat's FREE daily newsletter.

Genetic Technologies (ASX:GTG) Frequently Asked Questions

Has Genetic Technologies been receiving favorable news coverage?

Headlines about GTG stock have trended negative on Sunday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genetic Technologies earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Genetic Technologies.

Who are some of Genetic Technologies' key competitors?

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the following people:
  • Dr. Jerzy Muchnicki, Interim CEO & Director (Age 63, Pay $89.68k)
  • Dr. Richard Allman, Scientific Director (Age 60, Pay $265.91k)
  • Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, Consultant
  • Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA, Chief Financial Officer (Age 59)
  • Mr. Stan Sack, Chief Operating Officer

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the ASX under the ticker symbol "GTG."

How big of a company is Genetic Technologies?

Genetic Technologies has a market capitalization of $0.00 and generates $7,628.00 in revenue each year.

What is Genetic Technologies' official website?

The official website for Genetic Technologies is www.gtglabs.com.

How can I contact Genetic Technologies?

The company can be reached via phone at 61 3 8412 7000.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.